Compare Abeona Therapeutics Inc (ABEO) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Kingsoft Cloud Holdings Limited trades at $10.59 (market cap $2.80B). The key difference: Kingsoft Cloud Holdings Limited is far larger — about 7.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| ABEO | KC | |
|---|---|---|
Market Cap | $373.32M | $2.80B |
Sector | Health | Technology |
52-Week High | $7.23 | $18.21 |
52-Week Low | $4.17 | $8.58 |
Enterprise Value | $228.22M | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kingsoft Cloud (KC) trades at $9.13 with a slight 0.33% daily gain, showing technical bearish signals despite recent earnings beats. The company reported $9.56B revenue for 2025 but continues to post net losses (-$936M), though AI-driven cloud demand is accelerating growth. Analyst sentiment remains positive with 70% buy ratings, while technical indicators show mixed signals with RSI levels suggesting potential oversold conditions.
KC presents a growth story fueled by AI cloud services expansion, but profitability challenges and negative margins create investor uncertainty. The stock's appeal hinges on management's ability to convert revenue growth into sustainable profits amid heavy infrastructure investments. Near-term catalysts include Q2 2026 earnings and margin improvement progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
